- Home
- PGNY vs OCS Comparison
PGNY vs OCS Comparison
Compare PGNY & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGNY | OCS |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 60 |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PGNY | OCS |
|---|---|---|
| Price | $23.02 | $29.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $26.50 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 1.5M | 464.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.04 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $1,288,661,000.00 | N/A |
| Revenue This Year | $8.87 | $466.06 |
| Revenue Next Year | $9.76 | $479.73 |
| P/E Ratio | $79.31 | ★ N/A |
| Revenue Growth | ★ 10.40 | N/A |
| 52 Week Low | $16.10 | $16.00 |
| 52 Week High | $28.75 | $34.48 |
Technical Indicators
Market Signals| Indicator | PGNY | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 69.54 | 54.31 |
| Support Level | $21.93 | $25.95 |
| Resistance Level | $24.06 | $30.68 |
| Average True Range (ATR) | 0.90 | 1.49 |
| MACD | 0.46 | 0.15 |
| Stochastic Oscillator | 76.54 | 44.48 |
Price Performance
Historical ComparisonAbout PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.